Literature DB >> 20718738

Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion.

X Wu1, T Kihara, H Hongo, A Akaike, T Niidome, H Sugimoto.   

Abstract

BACKGROUND AND
PURPOSE: Several clinical trials and in vivo animal experiments have suggested that blockade of angiotensin receptor type 1 (AT(1)) improves ischaemic outcomes. However, the mechanism(s) underlying these effects has not been elucidated. Here, we have investigated the protective effects of pretreatment with AT(1) receptor antagonists, losartan or telmisartan, against ischaemic insult to neurons in vitro. EXPERIMENTAL APPROACH: Primary rat neuron-astrocyte co-cultures and astrocyte-defined medium (ADM)-cultured pure astrocyte cultures were prepared. Ischaemic injury was modelled by oxygen-glucose depletion (OGD) and lactate dehydrogenase release after OGD was measured with or without AT(1) receptor antagonists or agonists (L162313), AT(2) receptor antagonist (PD123319) or agonist (CGP-42112A) pretreatment, for 48 h. Activity of glutamate transporter 1 (GLT-1) was evaluated by [(3)H]-glutamate uptake assays, after AT(1) receptor agonists or antagonists. Immunoblot and real-time PCR were used for analysis of protein and mRNA levels of GLT-1. KEY
RESULTS: AT(1) receptor agonists augmented OGD-induced cellular damage, which was attenuated by AT(1) receptor antagonists. AT(1) receptor antagonists also suppressed OGD-induced extracellular glutamate release, reactive oxygen species production and nitric oxide generation. GLT-1 expression and glutamate uptake activity were significantly enhanced by AT(1) receptor antagonists and impaired by AT(1) receptor agonists. AT(1) receptor stimulation suppressed both ADM-induced GLT-1 protein expression and mRNA levels. AT(1)b receptor knock-down with siRNA enhanced GLT-1 expression. In postnatal (P1-P21) rat brains, protein levels of GLT-1 and AT(1) receptors were inversely correlated. CONCLUSIONS AND IMPLICATIONS: Suppression of AT(1) receptor stimulation induced GLT-1 up-regulation, which ameliorated effects of ischaemic injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718738      PMCID: PMC2962815          DOI: 10.1111/j.1476-5381.2010.00840.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

Review 1.  Mechanisms, challenges and opportunities in stroke.

Authors:  Eng H Lo; Turgay Dalkara; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2003-05       Impact factor: 34.870

Review 2.  Functions of angiotensin in the central nervous system.

Authors:  M I Phillips
Journal:  Annu Rev Physiol       Date:  1987       Impact factor: 19.318

Review 3.  Role of angiotensin in autoregulation of cerebral blood flow.

Authors:  O B Paulson; G Waldemar; A R Andersen; D I Barry; E V Pedersen; J F Schmidt; S Vorstrup
Journal:  Circulation       Date:  1988-06       Impact factor: 29.690

4.  Angiotensin II receptor subtypes are coupled with distinct signal-transduction mechanisms in neurons and astrocytes from rat brain.

Authors:  C Sumners; W Tang; B Zelezna; M K Raizada
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

5.  Identification of renin and angiotensinogen messenger RNA sequences in mouse and rat brains.

Authors:  V J Dzau; J Ingelfinger; R E Pratt; K E Ellison
Journal:  Hypertension       Date:  1986-06       Impact factor: 10.190

Review 6.  Mechanisms of excitotoxicity in neurologic diseases.

Authors:  M F Beal
Journal:  FASEB J       Date:  1992-12       Impact factor: 5.191

7.  Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

Authors:  S Perlman; H T Schambye; R A Rivero; W J Greenlee; S A Hjorth; T W Schwartz
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

8.  Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity.

Authors:  Y Tamura; Y Sato; A Akaike; H Shiomi
Journal:  Brain Res       Date:  1992-10-02       Impact factor: 3.252

Review 9.  Angiotensins in Alzheimer's disease - friend or foe?

Authors:  Patrick G Kehoe; Scott Miners; Seth Love
Journal:  Trends Neurosci       Date:  2009-09-30       Impact factor: 13.837

10.  Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.

Authors:  R Gyurko; D Wielbo; M I Phillips
Journal:  Regul Pept       Date:  1993-12-10
View more
  11 in total

1.  Losartan prevents acquired epilepsy via TGF-β signaling suppression.

Authors:  Guy Bar-Klein; Luisa P Cacheaux; Lyn Kamintsky; Ofer Prager; Itai Weissberg; Karl Schoknecht; Paul Cheng; Soo Young Kim; Lydia Wood; Uwe Heinemann; Daniela Kaufer; Alon Friedman
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

2.  Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury.

Authors:  Abdelrahman Y Fouda; Bindu Pillai; Krishnan M Dhandapani; Adviye Ergul; Susan C Fagan
Journal:  Eur J Pharmacol       Date:  2017-02-10       Impact factor: 4.432

Review 3.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

4.  The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy.

Authors:  SeungJu Jackie Oh; Xiaoduo Fan
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

5.  Evaluation and comparison of anticonvulsant activity of telmisartan and olmesartan in experimentally induced animal models of epilepsy.

Authors:  Pushpa V H; Padmaja Shetty K; Suresha R N; Jayanthi M K; Ashwini V; Vaibhavi P S
Journal:  J Clin Diagn Res       Date:  2014-10-20

Review 6.  Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

7.  Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/β-Catenin Signaling in Hypertension.

Authors:  Shahnawaz Ali Bhat; Ruby Goel; Shubha Shukla; Rakesh Shukla; Kashif Hanif
Journal:  Mol Neurobiol       Date:  2017-09-07       Impact factor: 5.590

8.  The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.

Authors:  Patricia K Sonsalla; Christal Coleman; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Bharathi S Gadad; Wenhao Li; Dwight C German
Journal:  Exp Neurol       Date:  2013-10-30       Impact factor: 5.330

Review 9.  Novel drugs and their targets in the potential treatment of diabetic retinopathy.

Authors:  Mohd Imtiaz Nawaz; Marwan Abouammoh; Haseeb A Khan; Abdullah S Alhomida; Mubarak F Alfaran; Mohammad Shamsul Ola
Journal:  Med Sci Monit       Date:  2013-04-26

Review 10.  Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Takashi Ito; Yoko Morimoto-Yamashita; Naoki Miura; Ko-ichi Kawahara; Ikuro Maruyama; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.